Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of HY-0902 versus febuxostat in gout with hyperuricemia
CTR20250718Phase 2Completed
- Sponsor
- Shandong Haiya Pharmaceutical Technology
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HY-0902 in gout and hyperuricemia (2 arms), sponsored by Shandong Haiya Pharmaceutical Technology. Primary endpoint: Proportion of participants with serum uric acid <360 umol/L at week 12. Started Mar 2025; status: completed.
02
Drugs
HY-0902
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20250718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250718.